The synergism between PARPi and TOP-1 inhibitors was further demonstrated using a HCT116 xenograft model, in which a combination regimen of IT and rucaparib strongly reduced tumor growth in vivo [59]. This evidence concerns the gene TOP1 and neoplasm.